Biological E Gets CDSCO Panel Nod To Study Inactivated Poliomyelitis Vaccine
Biological E Limited, a prominent Indian vaccine manufacturer, has received approval from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) to conduct a Phase III clinical trial for its inactivated poliomyelitis vaccine. This vaccine is intended for administration to healthy infants aged 6 to 8 weeks, following a dosing schedule […]
Biological E Gets CDSCO Panel Nod To Study Inactivated Poliomyelitis Vaccine Read More »